Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.

Authors Yarmolinsky J, Bouras E, Constantinescu A, et al, and Tsilidis KK.
Citation Diabetologia. 2023 Aug;66(8):1481-1500.
PubMedLink https://pubmed.ncbi.nlm.nih.gov/37171501
PMCID PMC10317892

Read this next

Genetically determined circulating resistin concentrations and risk of colorectal cancer: a two-sample Mendelian randomization study.

Leave a Reply